Nilotinib
| Code | Size | Price |
|---|
| SYN-1057-M100 | 100 mg | Enquire |
Quantity:
| SYN-1057-M001 | 1 mg | £69.00 |
Quantity:
| SYN-1057-M005 | 5 mg | £92.00 |
Quantity:
| SYN-1057-M010 | 10 mg | £127.00 |
Quantity:
| SYN-1057-M050 | 50 mg | £186.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
AMN107; Tasigna
Appearance:
Solid.
CAS:
641571-10-0
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS08
Hazards:
H361
InChi:
InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
InChiKey:
HHZIURLSWUIHRB-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 641571-10-0. Formula: C28H22F3N7O. MW: 529.5. Nilotinib is an orally bio-available aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor (IC(50) <30nM) with anti-neoplastic activity.
Molecular Formula:
C28H22F3N7O
Molecular Weight:
529.5
Package Type:
Plastic Vial
Precautions:
P201, P202, P281, P308, P313, P405, P501
Product Description:
Nilotinib is an orally bio-available aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor (IC(50) <30nM) with anti-neoplastic activity.
Purity:
>95%
Signal word:
Warning
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl: E. Weisberg, et al.; Cancer Cell. 7, 129 (2005)
Related Products
| Product Name | Product Code | Supplier | Genistein | AG-CN2-0427 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|